3-D Sys Corp Del Stock Price, News & Analysis

3D Systems Corporation (NYSE: DDD) reported a 15.3% decrease in revenue to $132.3 million for Q3 2022, impacted by divestitures and a decline in dental market sales. Despite challenges, non-GAAP revenue, excluding divestitures, grew 2.7%. The company experienced a net loss of $(37.4) million and a diluted loss per share of $(0.30). Adjusted EBITDA stood at $(0.3) million, reflecting inflationary pressures. Cash and short-term investments totaled $609.4 million. FY 2022 revenue guidance was revised to $535 - $545 million, with improved outlook on operating expenses.

3D Systems (NYSE: DDD) will release its third quarter 2022 financial results after U.S. markets close on November 8, 2022. A conference call and webcast to discuss the results will be held on November 9, 2022, at 8:30 a.m. ET. The company has been a leader in additive manufacturing solutions for over 35 years, serving various industries including healthcare, aerospace, and automotive. Investors can access the webcast and replay through the company's investor relations website.

3D Systems (NYSE: DDD) announced that Amnovis, a Belgium-based additive manufacturing company, has integrated the DMP Flex 350 Dual into its production workflow. This dual-laser solution enhances productivity by at least 50% compared to single-laser systems while reducing costs. Amnovis aims to leverage this technology for high-quality medical devices and industrial applications. The DMP Flex 350 Dual offers flexible application use and efficient management of print jobs, contributing to a competitive edge in both medical and industrial sectors.

3D Systems (NYSE:DDD) will participate in William Blair’s virtual panel, “Advancing Healthcare Through 3D Bioprinting,” on September 23, 2022, at 12:00 p.m. ET. This event highlights advancements in healthcare via 3D printing technology. A recording will be accessible on their website post-event for seven days. With over 35 years of experience, 3D Systems leads in additive manufacturing, offering tailored solutions in diverse sectors like healthcare, aerospace, and automotive.

3D Systems (NYSE:DDD) has announced that Andrew Johnson, executive vice president and chief legal officer, will also serve as chief corporate development officer. This dual role includes overseeing mergers and acquisitions and forging new strategic partnerships. Johnson's extensive experience, including the completion of over 60 M&A transactions, positions him well for these expanded responsibilities. The company aims to capitalize on emerging opportunities in regenerative medicine through strategic partnerships, leveraging its recent acquisitions and technological advancements.

3D Systems announced two new production-grade materials: Figure 4 Tough Clear and DuraForm PAx Black. Figure 4 Tough Clear is the company's first clear material designed for long-term use, featuring enhanced clarity and mechanical properties for applications like lenses and consumer goods. DuraForm PAx Black offers injection-molding-like properties with low-temperature printing, high impact resistance, and significant long-term stability. Both materials aim to facilitate rapid production and integration into existing workflows, targeting various industrial applications. Availability is set for Q4 2022.

3D Systems (NYSE:DDD) has announced the launch of a new biotech company, Systemic Bio, aimed at revolutionizing drug development by leveraging advanced bioprinting technologies. The company will utilize its proprietary h-VIOS™ organ-on-a-chip platform to create vascularized human tissues for drug testing, potentially reducing costs and the reliance on animal testing. Initial seed funding of $15 million is provided, with expected revenues nearing $100 million annually within five years. Taci Pereira is appointed as CEO, bringing extensive experience in bioengineering.

3D Systems has partnered with HII to develop the copper-nickel alloy CuNi30, designed for direct metal printing. This innovation can potentially reduce lead times by up to 75%, addressing the needs in marine, offshore oil & gas, and chemical industries. The alloy boasts an average relative density of 99.88%, significantly surpassing traditional casting methods. CuNi30 will be available in Q4 2022, enhancing supply chain efficiency while minimizing inventory costs. This advancement could revolutionize manufacturing processes in sectors requiring corrosion-resistant materials.

3D Systems (NYSE:DDD) has appointed Dr. Toby Cosgrove and Dr. Bon Ku to its Medical Advisory Board, expanding its expertise in regenerative medicine. Dr. Cosgrove, former CEO of the Cleveland Clinic, brings extensive healthcare leadership and innovation experience. Dr. Ku, a leader in healthcare technology, directs the Health Design Lab at Thomas Jefferson University. Their appointments aim to enhance 3D Systems' growth in areas like human tissue printing and medical device innovation. Both professionals are expected to contribute significantly to the company’s strategic direction.